

Adherium conducts A\$0.35m Placement to Institutional Investor

Summary:

- Firm commitments received for A\$0.35M institutional placement (before costs) at A\$0.005 per share
- The proceeds, together with existing cash reserves and proceeds from the recent ANREO will allow Adherium to execute on its growth plan and provide balance sheet strength.

Melbourne, Australia – 4 August 2025: is pleased to announce that it has received firm commitments from sophisticated and professional investors to raise approximately A\$0.35M (before costs) through an institutional placement (the "Placement").

The Placement was undertaken on the same terms as the recent partially underwritten Accelerated Non-Renounceable Entitlement Offer (the "ANREO"), which was fully subscribed and raised \$4.492M. This Placement represents the additional institutional demand that could not be allocated through the ANREO process.

The proceeds will be used to improve financial flexibility and working capital of the Company.

Adherium CEO, Ms Dawn Bitz, commented: "We are pleased with the strong support shown for the Company by both our existing shareholders and new institutional investors. Importantly, this capital raise ensures that Adherium is well funded to pursue both organic growth opportunities. With a strengthened balance sheet and additional working capital funding, we are well positioned to execute on our strategic objectives."

Details of the Placement

Institutional Placement to raise approximately A\$0.35 million via the issue of 70.2 million new fully paid ordinary shares ("New Shares") at A\$0.005 per New Share ("Placement Price"). Mr Keven Gessner, a director of the Company has committed subject to shareholder approval to take \$20,000 in the Placement. His participation is subject to shareholder approval at the 2025 AGM.

As per the terms of the ANREO, the Placement also includes the issue of 1 accompanying unlisted option for every 1 New Share issued under the Placement ("New Options"). The New Options will have an exercise price of \$0.005 each and expiry date 31 July 2026.

In addition, for every New Option exercised on or before 5 pm (AEDT) on 15 November 2025, the Company will issue one free option to acquire a Share with an exercise price of \$0.005 and expiring at 5pm on 15 November 2026 ("Bonus Options"). The terms and conditions of the New Options and Bonus Options are attached in Schedule 1 of an ASX announcement dated 24 June 2025.

All New Shares issued under the Capital Raise will rank equally with existing Shares of the Company from their issue date. The Placement is not subject to shareholder approval and will

For personal use only



ASX Release

fall within the Company's placement capacity under ASX Listing Rule 7.1 (with the exception of the issue of the Director Shares, which is subject to shareholder approval). The Placement is expected to settle today, 4 August 2025.

PAC Partners and Stralis Capital acted as joint lead managers to the Placement.

For more information about Adherium and its revolutionary respiratory solutions, please visit adherium.com.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries
investors@adherium.com

Media Enquiries:
Haley Chartres
HACK
Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at adherium.com

For personal use only